At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 342 enrolled
Drug / intervention
Rovalpituzumab tesirinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
In Brief
A Phase 2 clinical trial evaluating Rovalpituzumab tesirine for Small Cell Lung Cancer. Completed, enrolled 342 participants.
Detailed Summary
The purpose of this study is to determine the efficacy of rovalpituzumab tesirine as a third-line and later treatment for participants with relapsed or refractory delta-like protein 3 (DLL3) expressing small cell lung cancer (SCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Cancer
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJan 2016
First PostedFeb 2016
Primary CompletionOct 2018
TodayJul 2026
First PostedFeb 4, 2016
Enrollment StartJan 25, 2016
Primary CompletionOct 19, 2018
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 10.4 years ago
Interventions
Rovalpituzumab tesirinedrug
Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).